JPWO2020210485A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020210485A5
JPWO2020210485A5 JP2021559848A JP2021559848A JPWO2020210485A5 JP WO2020210485 A5 JPWO2020210485 A5 JP WO2020210485A5 JP 2021559848 A JP2021559848 A JP 2021559848A JP 2021559848 A JP2021559848 A JP 2021559848A JP WO2020210485 A5 JPWO2020210485 A5 JP WO2020210485A5
Authority
JP
Japan
Prior art keywords
formula
compound
protecting group
group
nitrogen protecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559848A
Other languages
Japanese (ja)
Other versions
JP2022527213A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027459 external-priority patent/WO2020210485A1/en
Publication of JP2022527213A publication Critical patent/JP2022527213A/en
Publication of JPWO2020210485A5 publication Critical patent/JPWO2020210485A5/ja
Withdrawn legal-status Critical Current

Links

Description

特定の態様では、本開示は、式(I)

Figure 2020210485000001
の化合物、または医薬として許容可能なその塩を調製するプロセスを提供しており、同プロセスは、式(XXII)の化合物を、式(VIII)の化合物と反応させて、それにより、式(XXIII)の化合物を生成することを含み:
Figure 2020210485000002
式中、
は、脱離基(
Figure 2020210485000003
など)である;Rは、2-フルオロベンジルまたは酸素保護基である。特定の好ましい実施形態では、Rは、2-フルオロベンジルである。特定の好ましい実施形態では、Rは、tert-ブチルオキシカルボニル(Boc);9-フルオレニルメチルオキシカルボニル(Fmoc);アセチル(Ac);ベンゾイル(Bz);カルバメート;トシル(Ts);Nosyl及びNpsから選択するスルホンアミド、及びトリフルオロアセチルから選択する窒素保護基などの共鳴受容性窒素保護基である。特定の好ましい実施形態では、Rは、tert-ブチルオキシカルボニル(Boc)である。特定の実施形態では、Rは、C1-6アルキル、C2-6アルケニル、またはC2-6アルキニルであり、最も好ましくは、メチルである。特定の実施形態では、プロセスは、式(XXIII)の化合物を調製するためのものである。 In certain aspects, the present disclosure provides compounds of formula (I)
Figure 2020210485000001
or a pharmaceutically acceptable salt thereof, wherein the process comprises reacting a compound of formula (XXII) with a compound of formula (VIII) to give a compound of formula (XXIII ) to produce a compound of:
Figure 2020210485000002
During the ceremony,
L3 is a leaving group (
Figure 2020210485000003
etc. ); R 5 is 2-fluorobenzyl or an oxygen protecting group. In certain preferred embodiments, R 5 is 2-fluorobenzyl. In certain preferred embodiments, R 6 is tert-butyloxycarbonyl (Boc); 9-fluorenylmethyloxycarbonyl (Fmoc); acetyl (Ac); benzoyl (Bz); carbamate; and Nps, and resonance accepting nitrogen protecting groups such as nitrogen protecting groups selected from trifluoroacetyl. In certain preferred embodiments, R 6 is tert-butyloxycarbonyl (Boc). In certain embodiments, R 8 is C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, most preferably methyl. In certain embodiments, the process is for preparing compounds of formula (XXIII).

用語「アミン」及び「アミノ」は、当該技術分野で認識されており、そして、非置換及び置換アミンの両方、及びそれらの塩のことを指しており、例えば、部分は、

Figure 2020210485000004
で表すことができ、
式中、R、R10、及びR10’は、それぞれ独立して、水素またはヒドロカルビル基を表す、または、R及びR10は、それらが結合するN原子と共に互いに結合して、その環状構造に4~8個の原子を有する複素環を完成する The terms "amine" and "amino" are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., the moiety
Figure 2020210485000004
can be expressed as
wherein R 9 , R 10 , and R 10 ′ each independently represent hydrogen or a hydrocarbyl group, or R 9 and R 10 are bonded together with the N atom to which they are bonded to form the cyclic Complete heterocycles with 4-8 atoms in the structure .

用語「カルバメート」は、当該技術分野で認識されており、そして、基

Figure 2020210485000005
のことを指しており、式中、R及びR10は、独立して、水素またはヒドロカルビル基を表す。 The term "carbamate" is art-recognized and
Figure 2020210485000005
wherein R 9 and R 10 independently represent hydrogen or hydrocarbyl groups.

Claims (1)

式(I)の化合物
Figure 2020210485000001
または医薬として許容可能なその塩を調製するためのプロセスであって、リチウムビス(トリメチルシリルアミドなどの塩基の存在下で、式(III)の化合物を、式(IV)の化合物と反応させて、それにより、式(V)の化合物を生成することを含み:
Figure 2020210485000002
式中:
は、脱離基である:
は、酸素保護基である;
は、共鳴受容性窒素保護基である;及び
は、C1-6アルキル、C2-6アルケニル、または、C2-6アルキニルである、前記プロセス。
Compounds of Formula (I)
Figure 2020210485000001
or a process for preparing a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (III) with a compound of formula (IV) in the presence of a base such as lithium bis(trimethylsilyl ) amide and thereby producing a compound of formula (V):
Figure 2020210485000002
In the formula:
L 1 is a leaving group:
R 1 is an oxygen protecting group;
The above process wherein R 2 is a resonance-accepting nitrogen protecting group; and R 3 is C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl.
JP2021559848A 2019-04-10 2020-04-09 Process for preparing alpha-carboxamide pyrrolidine derivatives Withdrawn JP2022527213A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831962P 2019-04-10 2019-04-10
US62/831,962 2019-04-10
PCT/US2020/027459 WO2020210485A1 (en) 2019-04-10 2020-04-09 Process for preparing alpha-carboxamide pyrrolidine derivatives

Publications (2)

Publication Number Publication Date
JP2022527213A JP2022527213A (en) 2022-05-31
JPWO2020210485A5 true JPWO2020210485A5 (en) 2023-05-17

Family

ID=72750576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559848A Withdrawn JP2022527213A (en) 2019-04-10 2020-04-09 Process for preparing alpha-carboxamide pyrrolidine derivatives

Country Status (12)

Country Link
US (1) US20220177426A1 (en)
EP (1) EP3953329A4 (en)
JP (1) JP2022527213A (en)
KR (1) KR20210150527A (en)
CN (1) CN114026066A (en)
AU (1) AU2020271856A1 (en)
BR (1) BR112021020345A2 (en)
CA (1) CA3136536A1 (en)
EA (1) EA202192762A1 (en)
IL (1) IL287078A (en)
MX (1) MX2021012420A (en)
WO (1) WO2020210485A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3691634A4 (en) 2017-10-05 2021-03-31 Biogen Inc. Process for preparing alpha-carboxamide pyrolidine derivatives
CN112812048B (en) * 2021-01-20 2022-08-26 北京蓝博特科技有限公司 Preparation method of sodium ion channel retarder CNV1014802 hydrochloride form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164597A (en) * 1962-12-17 1965-01-05 Geigy Chem Corp 5-carboxylic acid-2-phenyl-pyrrolines, corresponding pyrrolidines and functional derivatives thereof
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
WO2008090114A1 (en) * 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
ES2912881T3 (en) * 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedure for preparing alpha-carboxamide pyrrolidine derivatives
US9624169B2 (en) * 2015-03-27 2017-04-18 Scifluor Life Sciences, Inc. Aryl- and heteroaryl-pyrrolidine-2-carboxamide compounds

Similar Documents

Publication Publication Date Title
JP2022095872A5 (en)
RU2005123485A (en) DERIVATIVES OF PHOSPHONOOXYCHINAZOLINE AND THEIR PHARMACEUTICAL USE
JP2008509166A5 (en)
KR880009041A (en) Peptide derivatives, their preparation and use
JP2006507265A5 (en)
KR890003679A (en) Esters and Amides of Cyclic Carboxylic Acids and Cyclic Alcohols and Amines
JP2011527686A5 (en)
US7553969B1 (en) Substituted phenethylamine derivatives
JP2005511699A5 (en)
KR920018053A (en) Novel 8-substituted purines as selective adenosine receptors
CA2940455A1 (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
CA2085715A1 (en) Aminosulfonic acid derivatives and processes for their preparation
JPWO2020004649A5 (en)
JPH08508720A (en) Pyrrole-amidine compound and pharmaceutically acceptable salt thereof, process for producing the same and pharmaceutical composition containing the same
EP3344603A1 (en) A production method of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin- 4 yl)urea and its deuterated analogs not containing dimeric impurities
WO2023022231A1 (en) Reversible covalent binding inhibitor for treating or preventing viral infection
JPWO2022038299A5 (en)
PT1443046E (en) Novel 4-(2furoyl)aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
JPWO2020210485A5 (en)
JPH05500949A (en) Gem-diphosphonic acid, its production method, and pharmaceutical compositions containing the same
NZ231750A (en) Retroviral protease inhibitors and pharmaceutical compositions
JP2004529172A5 (en)
Alexakis et al. A practical and efficient synthesis of chiral N, N-disubstituted C2 symmetric diamines derived from (R, R)-1, 2-diaminocyclohexane
JPWO2019213445A5 (en)
JP2015532915A (en) Method for producing bortezomib